Article Text

PDF

Daunorubicin
  1. Rae N. Matthews,
  2. John H. Colebatch

    Results in Childhood Leukaemia

    Abstract

    Fifty children with acute leukaemia (44 lymphatic, 6 myeloid) were treated with daunorubicin. In 3 cases, it was given in courses of daily injections; in 47, single injections were given at 7- to 14-day intervals. On the latter (intermittent) regimen, in combination with prednisolone, a good response—complete, bone marrow, or clinical remission—occurred in 22 of 27 cases (81%) of `new' or previously untreated acute lymphoblastic leukaemia but in only 3 of 13 cases previously treated with other drugs. With acute myeloid leukaemia a good response occurred only when daunorubicin was given in combination with other cytotoxic drugs. The major side-effect was bone marrow depression with the related complications of haemorrhage and infection. Cardiotoxicity was not a problem; the cumulative total dose of daunorubicin did not exceed 26·8 mg/kg. This study indicates that intermittent dosage with 2-3 mg/kg at intervals of 7 to 14 days is as effective as, and no more toxic than, the courses of daily injections that have been commonly used.

    Statistics from Altmetric.com

    Results in Childhood Leukaemia

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.